Published in J Theor Biol on January 12, 2011
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet (2011) 6.21
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infect Dis (2013) 1.65
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis (2013) 1.38
Identification of hepatitis C virus transmission using a next-generation sequencing approach. J Clin Microbiol (2012) 1.00
Hepatitis C transmission and treatment in contact networks of people who inject drugs. PLoS One (2013) 0.98
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS (2015) 0.90
Errors in reported degrees and respondent driven sampling: implications for bias. Drug Alcohol Depend (2014) 0.85
Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? PLoS One (2015) 0.84
Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence (2013) 0.83
Optimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug users. PLoS One (2011) 0.83
Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges. Virulence (2015) 0.82
Should malaria treatment be guided by a point of care rapid test? A threshold approach to malaria management in rural Burkina Faso. PLoS One (2013) 0.82
Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One (2015) 0.80
Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis (2015) 0.77
A theoretical model for the transmission dynamics of the Buruli ulcer with saturated treatment. Comput Math Methods Med (2014) 0.77
Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. Hepatology (2016) 0.76
Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: Is elimination possible in a high prevalence setting? Addiction (2017) 0.75
Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. Addict Disord Their Treat (2017) 0.75
Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs. AIDS Rev (2017) 0.75
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet (2008) 11.44
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet (2010) 8.02
Global overview of injecting drug use and HIV infection among injecting drug users. AIDS (2004) 5.45
How ideology shapes the evidence and the policy: what do we know about cannabis use and what should we do? Addiction (2010) 5.08
Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ (2010) 3.59
Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ (2012) 3.46
Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet (2010) 3.29
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction (2011) 2.95
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology (2013) 2.76
Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction (2010) 2.59
Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis (2010) 2.56
Methods to recruit hard-to-reach groups: comparing two chain referral sampling methods of recruiting injecting drug users across nine studies in Russia and Estonia. J Urban Health (2006) 2.52
Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction (2006) 2.46
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction (2012) 2.45
Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia. AIDS (2002) 2.40
If cannabis caused schizophrenia--how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations. Addiction (2009) 2.25
Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction (2007) 2.20
Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis. Int J Epidemiol (2013) 2.08
Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction (2006) 2.06
Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ (2004) 2.03
Drug-related mortality and its impact on adult mortality in eight European countries. Eur J Public Health (2005) 2.01
Access and coverage of needle and syringe programmes (NSP) in Central and Eastern Europe and Central Asia. Addiction (2007) 1.95
Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine (2013) 1.94
Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5"). Addiction (2006) 1.87
Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J Med Virol (2003) 1.84
Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction (2007) 1.81
Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004. Int J Epidemiol (2006) 1.78
Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology (2011) 1.67
Adolescent alcohol and tobacco use and early socioeconomic position: the ALSPAC birth cohort. Pediatrics (2011) 1.60
Estimating long-term trends in the incidence and prevalence of opiate use/injecting drug use and the number of former users: back-calculation methods and opiate overdose deaths. Am J Epidemiol (2004) 1.57
Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health (2007) 1.57
Childhood conduct disorder trajectories, prior risk factors and cannabis use at age 16: birth cohort study. Addiction (2013) 1.56
Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol (2011) 1.50
Trends in deaths related to drug misuse in England and Wales, 1993-2004. Health Stat Q (2006) 1.43
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis (2013) 1.38
Intrauterine exposure to alcohol and tobacco use and childhood IQ: findings from a parental-offspring comparison within the Avon Longitudinal Study of Parents and Children. Pediatr Res (2008) 1.38
Interim modelling analysis to validate reported increases in condom use and assess HIV infections averted among female sex workers and clients in southern India following a targeted HIV prevention programme. Sex Transm Infect (2010) 1.38
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust (2012) 1.33
Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health (2014) 1.30
Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction (2009) 1.30
Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS (2013) 1.28
Positive impact of a large-scale HIV prevention programme among female sex workers and clients in South India. AIDS (2013) 1.26
A dose-response relationship between exposure to a large-scale HIV preventive intervention and consistent condom use with different sexual partners of female sex workers in southern India. BMC Public Health (2011) 1.25
Condoms and prevention of HIV. BMJ (2004) 1.23
Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis (2008) 1.23
Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.23
Socio-economic status in childhood and later alcohol use: a systematic review. Addiction (2007) 1.21
Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health (2011) 1.20
The impact of out-migrants and out-migration on the HIV/AIDS epidemic: a case study from south-west India. AIDS (2008) 1.20
Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia. Int J STD AIDS (2005) 1.18
Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. Drug Alcohol Rev (2009) 1.16
Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. J Acquir Immune Defic Syndr (2006) 1.15
Parental drug use, early adversities, later childhood problems and children's use of tobacco and alcohol at age 10: birth cohort study. Addiction (2008) 1.14
Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh? Addiction (2007) 1.14
Reducing the burden of sexually transmitted infections in resource-limited settings: the role of improved diagnostics. Nature (2006) 1.13
Examining inequalities in the uptake of the school-based HPV vaccination programme in England: a retrospective cohort study. J Public Health (Oxf) (2013) 1.13
Low incidence of hepatitis C virus among prisoners in Scotland. Addiction (2013) 1.11
HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med (2012) 1.08
Characterizing patterns of smoking initiation in adolescence: comparison of methods for dealing with missing data. Nicotine Tob Res (2011) 1.06
The prevalence of injecting drug use in a Russian city: implications for harm reduction and coverage. Addiction (2004) 1.05
HIV transmission from drug injectors to partners who do not inject, and beyond: modelling the potential for a generalized heterosexual epidemic in St. Petersburg, Russia. Drug Alcohol Depend (2013) 1.04
Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend (2010) 1.04
Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission? Drug Alcohol Depend (2013) 1.03
Establishing the Melbourne Injecting Drug User Cohort Study (MIX): rationale, methods, and baseline and twelve-month follow-up results. Harm Reduct J (2013) 1.02
Patterns of alcohol use in early adolescence predict problem use at age 16. Alcohol Alcohol (2012) 1.02
Remodelling core group theory: the role of sustaining populations in HIV transmission. Sex Transm Infect (2010) 0.99
Policy resistance to harm reduction for drug users and potential effect of change. BMJ (2010) 0.98
Over a decade of syringe exchange: results from 1997 UK survey. Addiction (2002) 0.98
The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction (2004) 0.98
The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh. Addiction (2009) 0.97
Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settings--implications for intervention impact. Drug Alcohol Depend (2011) 0.96
Outcomes of childhood conduct problem trajectories in early adulthood: findings from the ALSPAC study. Eur Child Adolesc Psychiatry (2013) 0.96
Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again? Am J Epidemiol (2009) 0.95
Capturing crack cocaine use: estimating the prevalence of crack cocaine use in London using capture-recapture with covariates. Addiction (2005) 0.95
Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open (2013) 0.95
Testing a level of response to alcohol-based model of heavy drinking and alcohol problems in 1,905 17-year-olds. Alcohol Clin Exp Res (2011) 0.95
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis (2012) 0.95
HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS (2005) 0.94
Reporting bias and self-reported drug use. Addiction (2005) 0.94
Recapture or precapture? Fallibility of standard capture-recapture methods in the presence of referrals between sources. Am J Epidemiol (2014) 0.94
Maternal smoking during pregnancy and offspring smoking initiation: assessing the role of intrauterine exposure. Addiction (2014) 0.94
Adolescent cannabis and tobacco use and educational outcomes at age 16: birth cohort study. Addiction (2015) 0.93
Community mobilization and empowerment of female sex workers in Karnataka State, South India: associations with HIV and sexually transmitted infection risk. Am J Public Health (2014) 0.92
Mitigating the risk of HIV infection with opioid substitution treatment. Bull World Health Organ (2013) 0.91
The costs of HIV prevention for different target populations in Mumbai, Thane and Bangalore. BMC Public Health (2011) 0.91